Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

অনুরূপ উপাদানগুলি

• Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
  অনুযায়ী: E-E Ke, অন্যান্য
  প্রকাশিত: (2016-06-01)
• Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
  অনুযায়ী: Green, John A.
  প্রকাশিত: (2018)
• First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
  অনুযায়ী: Park, Keunchil, অন্যান্য
  প্রকাশিত: (2019)
• First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
  অনুযায়ী: Greenhalgh, Janette, অন্যান্য
  প্রকাশিত: (2021)
• Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study
  অনুযায়ী: Park, Keunchil
  প্রকাশিত: (2016)